Insider Trading Alert - RP, DAL And HCN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 21, 2014, 108 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $747.00 to $81,857,601.00.

Highlighted Stocks Traded by Insiders:

Realpage (RP) - FREE Research Report

Chaney William P, who is EVP Enterprise Solutions at Realpage, sold 1,800 shares at $16.10 on Aug. 21, 2014. Following this transaction, the EVP Enterprise Solutions owned 88,366 shares meaning that the stake was reduced by 2% with the 1,800-share transaction.

The shares most recently traded at $16.03, down $0.07, or 0.44% since the insider transaction. Historical insider transactions for Realpage go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 6,145
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 130,661
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 213,062

The average volume for Realpage has been 722,100 shares per day over the past 30 days. Realpage has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are down 31.35% year-to-date as of the close of trading on Thursday.

RealPage, Inc. provides on demand software solutions for the rental housing industry in North America. The company has a P/E ratio of 144.1. Currently, there is 1 analyst who rates Realpage a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RP - FREE

TheStreet Quant Ratings rates Realpage as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Realpage Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Delta Air Lines (DAL) - FREE Research Report

Hauenstein Glen W, who is EVP and Chief Revenue Officer at Delta Air Lines, sold 47,328 shares at $40.52 on Aug. 21, 2014. Following this transaction, the EVP and Chief Revenue Officer owned 189,995 shares meaning that the stake was reduced by 19.94% with the 47,328-share transaction.

The shares most recently traded at $40.29, down $0.23, or 0.56% since the insider transaction. Historical insider transactions for Delta Air Lines go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 197,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 222,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 322,927

The average volume for Delta Air Lines has been 12.8 million shares per day over the past 30 days. Delta Air Lines has a market cap of $34.2 billion and is part of the services sector and transportation industry. Shares are up 45.29% year-to-date as of the close of trading on Thursday.

Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo worldwide. Its route network comprises various gateway airports in Amsterdam, Atlanta, Cincinnati, Detroit, Memphis, Minneapolis-St. The stock currently has a dividend yield of 0.89%. The company has a P/E ratio of 3.2. Currently, there are 11 analysts who rate Delta Air Lines a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DAL - FREE

TheStreet Quant Ratings rates Delta Air Lines as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, attractive valuation levels, solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Delta Air Lines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Health Care REIT (HCN) - FREE Research Report

Ibele Erin C, who is EVP-Head Human Cap.&Corp.Secy. at Health Care REIT, sold 175 shares at $65.90 on Aug. 21, 2014. Following this transaction, the EVP-Head Human Cap.&Corp.Secy. owned 54,641 shares meaning that the stake was reduced by 0.32% with the 175-share transaction.

The shares most recently traded at $66.09, up $0.19, or 0.29% since the insider transaction. Historical insider transactions for Health Care REIT go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 10,416
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 15,091

The average volume for Health Care REIT has been 2.3 million shares per day over the past 30 days. Health Care REIT has a market cap of $20.5 billion and is part of the financial sector and real estate industry. Shares are up 23.89% year-to-date as of the close of trading on Thursday.

Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The stock currently has a dividend yield of 4.79%. The company has a P/E ratio of 127.6. Currently, there are 6 analysts who rate Health Care REIT a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCN - FREE

TheStreet Quant Ratings rates Health Care REIT as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, good cash flow from operations, increase in net income and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Health Care REIT Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing